Skip to main content
Equibles
PLX logo

PLX · Protalix BioTherapeutics, Inc. · Webcasts, Transcripts & Audio

Track PLX — free

Use PLX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PLX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.73 +0.02 (+0.74%)
Russell 2000 member Rebalance outlook locked
Market Cap
$219.15M
Shares
80.57M
Volume · Oct 6 934.74K Avg daily vol (3M) 720.45K

Protalix BioTherapeutics, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Protalix BioTherapeutics, Inc. (PLX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲17.7% $14.18M −$3.57M '22 Q3 22-11-14 ▲0.8% $8.62M −$3.74M '22 Q4 23-02-27 ▼40.4% $9.59M −$3.13M '23 Q1 23-05-04 ▲300.7% $35.08M $19.34M '23 Q2 23-08-07 ▼27.1% $10.35M −$1.85M '23 Q3 23-11-06 ▲21.7% $10.49M −$6.04M '23 Q4 24-03-14 ▼60.9% $3.75M −$4.59M '24 Q1 24-05-10 ▼61.6% $13.47M −$2.20M '24 Q2 24-08-14 ▲73.6% $17.96M $3.24M '24 Q3 24-11-14 ▲73.7% $18.22M $6.49M '24 Q4 25-03-17 ▲169.8% $10.11M −$3.62M '25 Q1 25-05-09 ▲16.2% $15.66M $164,000 '25 Q2 25-08-14 ▼0.6% $17.85M $2.35M '25 Q3 25-11-13 ▼49.9% $9.12M −$5.50M '25 Q4 26-03-18 ▲233.7% $33.75M $18.32M '26 Q1 26-05-13 LATEST ▲27.1% $19.90M $3.78M '26 Q2 26-08-12
Conference
Investor event
2026-09-16
Protalix BioTherapeutics, Inc. (PLX) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-12
Protalix BioTherapeutics, Inc. (PLX) Q2 2026 Earnings Call Transcript
Positive tone Phase 2 study regimens (E4W/E8W with/without methotrexate) Phase 3 dose selection and ADA/PK/PD considerations Elfabrio (commercial product) performance and lumpy orders
Revenue
$19.90M
▲ 27.1% YoY
Diluted EPS
$0.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-13
Protalix BioTherapeutics, Inc. (PLX) Q1 2026 Earnings Call Transcript
Positive tone Elfabrio every 4-week approval and commercial uptake PRX-115 Phase II RELEASE study in uncontrolled gout Balance sheet and financial flexibility
Revenue
$33.75M
▲ 233.7% YoY
Diluted EPS
$0.22
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-18
Protalix BioTherapeutics, Inc. (PLX) Q4 2025 Earnings Call Transcript
Confident tone Elfabrio EU Every-4-Weeks Approval Chiesi Partnership and Revenue Growth 2026 Revenue Guidance
Revenue
$9.12M*
▼ 49.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-13
Protalix BioTherapeutics, Inc. (PLX) Q3 2025 Earnings Call Transcript
Positive tone Quarterly and Year-to-Date Revenue Performance Elfabrio CHMP Reexamination (Q4W Dosing) PRX-115 Phase 2 Trial in Uncontrolled Gout
Revenue
$17.85M
▼ 0.6% YoY
Diluted EPS
$0.03
▲ 0% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
Protalix BioTherapeutics, Inc. (PLX) Q2 2025 Earnings Call Transcript
Positive tone Elfabrio Commercialization with Chiesi CFO Transition EMA Once-Every-4-Weeks Dosing Variation
Revenue
$15.66M
▲ 16.2% YoY
Diluted EPS
$0.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-09
Protalix BioTherapeutics, Inc. (PLX) Q1 2025 Earnings Call Transcript
Positive tone Tariffs and international tax exposure PRX-115 clinical development in gout Operating costs and R&D spend
Revenue
$10.11M
▲ 169.8% YoY
Diluted EPS
$-0.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-17
Protalix BioTherapeutics, Inc. (PLX) Q4 2024 Earnings Call
Revenue
$18.22M*
▲ 73.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-14
Protalix BioTherapeutics, Inc. (PLX) Q3 2024 Earnings Call Transcript
Positive tone PRX-115 Phase 1 results in uncontrolled gout Elfabrio commercialization with Chiesi PRX-115 Phase 2 planning
Revenue
$17.96M
▲ 73.6% YoY
Diluted EPS
$0.03
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Protalix BioTherapeutics, Inc. (PLX) Q2 2024 Earnings Call Transcript
Positive tone Elfabrio commercial sales with Chiesi PRX-115 for uncontrolled gout Financial results and revenue decline
Revenue
$13.47M
▼ 61.6% YoY
Diluted EPS
$-0.03
▼ 114.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-10
Protalix BioTherapeutics, Inc. (PLX) Q1 2024 Earnings Call Transcript
Positive tone PRX-115 Phase I gout program Elfabrio commercial launch and Chiesi partnership Japan BLA for Fabry
Revenue
$3.75M
▼ 60.9% YoY
Diluted EPS
$-0.06
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-14
Protalix BioTherapeutics, Inc. (PLX) Q4 2023 Earnings Call Transcript
Confident tone Elfabrio Commercial Launch and Approvals Revenue Growth and Financial Performance Chiesi Partnership and Pediatric/Japanese Expansion
Revenue
$10.49M*
▲ 21.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-06
Protalix BioTherapeutics, Inc. (PLX) Q3 2023 Earnings Call Transcript
Revenue
$10.35M
▼ 27.1% YoY
Diluted EPS
$-0.04
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Protalix BioTherapeutics, Inc. (PLX) Q2 2023 Earnings Call Transcript
Revenue
$35.08M
▲ 300.7% YoY
Diluted EPS
$0.21
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Protalix BioTherapeutics, Inc. (PLX) Q1 2023 Earnings Call Transcript
Revenue
$9.59M
▼ 40.4% YoY
Diluted EPS
$-0.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-27
Protalix BioTherapeutics, Inc. (PLX) Q4 2022 Earnings Call Transcript
Revenue
$8.62M*
▲ 0.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Protalix BioTherapeutics, Inc. (PLX) Q3 2022 Earnings Call Transcript
Revenue
$14.18M
▲ 17.7% YoY
Diluted EPS
$-0.07
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-15
Protalix BioTherapeutics, Inc. (PLX) Q2 2022 Earnings Call Transcript
Revenue
$8.75M
▲ 36.2% YoY
Diluted EPS
$-0.11
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-16
Protalix BioTherapeutics, Inc. (PLX) Q1 2022 Earnings Call Transcript
Revenue
$16.09M
▲ 42.1% YoY
Diluted EPS
$-0.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-31
Protalix BioTherapeutics, Inc. (PLX) Q4 2021 Earnings Call Transcript
Revenue
$8.55M*
▼ 56.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-15
Protalix BioTherapeutics, Inc. (PLX) Q3 2021 Earnings Call Transcript
Revenue
$12.05M
▲ 11.7% YoY
Diluted EPS
$-0.09
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-16
Protalix BioTherapeutics, Inc. (PLX) Q2 2021 Earnings Call Transcript
Revenue
$6.43M
▼ 41.4% YoY
Diluted EPS
$-0.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-14
Protalix BioTherapeutics, Inc. (PLX) Q1 2021 Earnings Call Transcript
Revenue
$11.32M
▼ 47.7% YoY
Diluted EPS
$-0.14
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-16
Protalix BioTherapeutics, Inc. (PLX) Q4 2020 Earnings Call Transcript
Revenue
$19.50M*
▲ 9.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-10-29
Protalix BioTherapeutics, Inc. (PLX) Q3 2020 Earnings Call Transcript
Revenue
$10.79M
▼ 24.3% YoY
Diluted EPS
$-0.14
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
Protalix BioTherapeutics, Inc. (PLX) Q2 2020 Earnings Call Transcript
Revenue
$10.97M
▼ 10.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-06-01
Protalix BioTherapeutics, Inc. (PLX) Q1 2020 Earnings Call Transcript
Revenue
$21.65M
▲ 107.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-12
Protalix BioTherapeutics, Inc. (PLX) Q4 2019 Earnings Call
Revenue
$17.76M*
▼ 34.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–28 of 28 webcasts
Key facts CIK 1006281 CUSIP 74365A309 13F (30d) 1 filings 1 filers Visit website Investor relations